News & Updates
Filter by Specialty:

Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
22 Jul 2024
Is it safe for T1D patients to exercise after a meal?
Individuals with type 1 diabetes (T1D) may engage in postprandial exercise so long as they take necessary precautions (ie, prandial insulin reductions), suggests a study.
Is it safe for T1D patients to exercise after a meal?
19 Jul 2024
Novel tool spots potentially inappropriate prescribing in T2D
A new tool for identifying potentially inappropriate prescribing (PIP) in people with type 2 diabetes (T2D) has been validated in the outpatient setting, according to an Ethiopian study.
Novel tool spots potentially inappropriate prescribing in T2D
18 Jul 2024
INHALE-3 underpins alternate insulin delivery method for T1D
Findings from the phase IV INHALE-3 trial support inhaled insulin for the management of type 1 diabetes (T1D) in adults, underlining its role as an alternative insulin solution to enhance diabetes management.
INHALE-3 underpins alternate insulin delivery method for T1D
17 Jul 2024
Automated insulin delivery system beneficial for T2D management
An automated insulin delivery (AID) system appears to improve clinical outcomes in people with type 2 diabetes (T2D), with the pivotal SECURE-T2D trial showing substantial improvements in glycated haemoglobin, total daily insulin dose, and diabetes distress, without increasing the risk of hypoglycaemia.